Home

The firm

Team

Portfolio

Investors

Connect

  • Loading stock data...

Fostering the next generation of Nordic and U.S. Life Sciences companies

Begin scrolling

Our firm

Empowering Visionaries at the Forefront of Growth

We are dedicated to supporting high-growth ventures and groundbreaking innovations poised to transform the life sciences sector. By providing the right resources and strategic support, we unlock their potential for creating significant value and driving substantial financial growth.

Strategic Support and Leadership for Breakthrough Success

We are committed to engaging, empowering, and capitalizing the businesses in our portfolio, actively driving their growth and success. Our comprehensive approach combines strategic counsel, operational expertise, and the cultivation of meaningful alliances with trusted partners, enabling these businesses to strengthen their market position and achieve their goals.

With a team of skilled Nordic and American professionals, we bring a unique blend of expertise and perspective to the table, delivering a distinctive and impactful approach to advancing business aspirations and unlocking their full potential.

Meet our dedicated directors and leadership here

The Nordicus Value Proposition

Nordicus Partners is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies.

Dual-Market Expertise

Leveraging Nordic innovation and U.S. operational know-how, to create a unique advantage in identifying, scaling and exiting high-potential companies with early- and mid-stage molecules.
Experienced team with operational experience, an expansive strategic partner network, and a proven ability to enhance portfolio company value.

Focus On High-Growth Markets With Unmet Medical Needs

Targeting transformative, scalable opportunities, including periodontal disease, oral leukoplakia (OLK), and central nervous system (CNS) disorders.

4-Step Value Creation Process

Scout and Accelerate: Target high-impact potential companies, providing capital, resources, and expertise to drive critical milestones such as patent filings and clinical trials.
Acquire and Exit: Acquire controlling stakes to maximize value creation and exit at premium multiples.

Connect With Nordicus

At Nordicus, we harness the transformative power of collaboration, uniting the innovative spirit of Nordic expertise with the operational strength of American insight. Beyond financial backing, we provide strategic guidance designed to unlock exceptional growth opportunities and drive meaningful results.

If your company is ready to achieve new milestones, connect with Nordicus. Together, let’s accelerate your growth and achieve success.

Review our current portfolio
Contact us
beststocks.com

Kim Mücke

Member, Board of Directors

Kim T. Mücke is a Danish state authorized public accountant (authorization deposited in 2025). He was partner with Deloitte (Denmark) in the period 2002 to 2022 where he – among others – served as signing partner for various listed companies including companies that underwent IPO processes. In the years 2023-2024, Mr. Mücke was Head of Corporate Clients for BDO (Denmark). From 1 January 2025, Mr. Mücke has started as independent advisor,specialized in financial reporting, risk management and corporate governance. Mr. Mücke has a master’s degree in Auditing and Accounting from the Copenhagen Business School.

Andrew Ritter

Member, Board of Directors

Mr. Ritter is a seasoned healthcare executive with over two decades of leadership experience across biotechnology, digital health, and other healthcare technologies. He has successfully led multiple company exits, taken a company public on NASDAQ, and advised leading private equity and venture capital firms throughout the investment lifecycle.

He began his career as the founder and CEO of Ritter Pharmaceuticals, a microbiome-based biotech company. Over 17 years, he advanced the company from early-stage development through Phase III clinical trials, led its IPO onto the NASDAQ, and later merged the company with QualigenTherapeutics. Following that success, Mr. Ritter led a turnaround and successful exit of Docbot, an AI-driven MedTech company. He is currently an Entrepreneur in Residence at Khosla Ventures, and serves as CEO of portfolio company Cairns Health, an AI-powered remote care solutions to support Home and Senior Care.

He has also served as a founding board member of Myosin Therapeutics, a biotech spin-out from Scripps Research, where he helped secure the company’s initial financing and supported its early growth. Mr. Ritter holds a B.A. in Political Science from the University of Southern California and an M.B.A. from the Wharton School of the University of Pennsylvania.